Reach your audience. Get results.
Rely on the experience, guidance, and superior media targeting of Business Wire for your global press release distribution.
Public RelationsMaximize the reach of your news with our press release distribution services and partnerships. Investor RelationsReach and engage investors, shareholders, analysts, and media with our complete suite of IR services and tools. Distribution & AnalyticsTarget your news, reach your audiences, and understand the impact of your press releases with our analytics reports. |
Latest News
Today is September 24, 2024.
All times in Eastern Daylight Time.
-
Une nouvelle startup d’IA agentique lance Integrail AI Studio, ouvrant la voie au développement d’applications d’IA sans codeSAN FRANCISCO--(BUSINESS WIRE)--Préparez-vous à révolutionner vos activités avec AI Studio by Integrail, une plateforme d’IA agentique sans code. Integrail est heureuse de lancer une plateforme rév... more »
-
Samenvatting: Nieuw agentic AI-startup lanceert Integrail AI Studio, toonaangevend in AI-applicatieontwikkeling zonder codeSAN FRANCISCO--(BUSINESS WIRE)--Bereid u voor op een revolutie in uw bedrijf met AI Studio van Integrail, een agentic no-code AI-platform. Integrail is verheugd om een baanbrekend platform te lance... more »
-
新的主動式人工智慧新創公司推出Integrail AI Studio,引領無程式碼人工智慧應用程式開發潮流舊金山--(BUSINESS WIRE)--(美國商業資訊)-- Integrail的AI Studio是一個無程式碼主動式人工智慧(Agentic AI)平台,它將徹底改變您的企業。Integrail隆重推出的這個開創性平台讓您無需編寫任何程式碼,即可創建強大的人工智慧應用程式。AI Studio旨在協助企業實現全部業務工作流程的自動化,讓每個人都能使用人工智慧。 認識夢想家團隊 Anto... more »
-
新的代理型人工智能初创公司推出Integrail AI Studio,引领无代码人工智能应用开发潮流旧金山--(BUSINESS WIRE)--(美国商业资讯)-- Integrail的AI Studio是一个无代码代理型人工智能(Agentic AI)平台,它将彻底改变您的企业。Integrail隆重推出的这一开创性平台让您无需编写任何代码,即可创建强大的人工智能应用程序。AI Studio旨在帮助企业实现全部业务工作流程的自动化,让每个人都能使用人工智能。 了解梦想家团队 Anton ... more »
-
「ニューリフィックス®」ベータグルカンがデュシェンヌ型筋ジストロフィー治療薬として希少小児疾患および希少疾病用医薬品の指定を米国FDAから取得東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 日本製の「ニューリフィックス®」 ベータグルカンが、デュシェンヌ型筋ジストロフィー(DMD)の治療薬として、米国食品医薬品局(US FDA)から希少小児疾患指定(RPDD)と希少疾病用医薬品指定(ODD)を取得しました。これらの指定は、日本およびインドで実施された前臨床試験及び臨床試験の進展を、米国でのFDA承認に向けた臨床... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
LONDON--(BUSINESS WIRE)-- DMO-TAS031/3342/003 The Minster Building21 Mincing LaneLondonEC3R 7AG T 020 7862 6500F 020 7862 6509www.dmo.gov.uk 24 September 2024 A146\24 PRESS NOTICE RESULT OF TH... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »